In a 78‑year‑old woman with a history of pulmonary embolism who stopped methotrexate three weeks ago and still has a persistent rash despite a skin biopsy, could the rash be a drug reaction to rivaroxaban (direct oral anticoagulant)?

Rivaroxaban is a Possible but Uncommon Cause of This Persistent Rash

Yes, rivaroxaban could be causing this rash, though it is relatively uncommon. Direct oral anticoagulants including rivaroxaban can cause cutaneous adverse reactions, and given that methotrexate discontinuation has not resolved the rash after three weeks, rivaroxaban should be strongly considered as the culprit.

Why Rivaroxaban Should Be Suspected

While the provided guidelines focus primarily on rivaroxaban's efficacy and bleeding risks in pulmonary embolism treatment 1, 2, drug-induced cutaneous reactions are well-recognized adverse effects of anticoagulants that may not be prominently featured in cardiovascular guidelines. The temporal relationship is key here:

• Methotrexate has been stopped for three weeks without improvement - this argues against methotrexate as the ongoing cause
• The patient remains on rivaroxaban - which she likely started around the time of her PE diagnosis
• Drug reactions can have delayed onset and may not appear immediately after drug initiation

Critical Diagnostic Steps

Examine the rash characteristics carefully:

• Look for petechiae, purpura, or ecchymoses (suggesting thrombocytopenia or vasculitis)
• Assess for urticarial lesions, maculopapular eruptions, or bullous changes
• Document distribution pattern (generalized vs. localized)

Review the skin biopsy results specifically for:

• Leukocytoclastic vasculitis (drug-induced hypersensitivity)
• Interface dermatitis patterns
• Eosinophilic infiltrates (suggesting drug reaction)
• Evidence of thrombotic microangiopathy

Check laboratory parameters:

• Complete blood count (rivaroxaban rarely causes thrombocytopenia)
• Renal function (affects rivaroxaban clearance and can worsen drug accumulation 3)
• Liver function tests
• Anti-factor Xa levels if available (to assess for drug accumulation)

Important Caveats About This Patient

Age and renal function matter significantly. At 78 years old, this patient has:

• Prolonged rivaroxaban half-life (11-13 hours in elderly vs. 5-9 hours in younger patients 4)
• Potentially reduced renal clearance (66% of rivaroxaban is renally excreted 4, 3)
• Higher risk of drug accumulation if creatinine clearance is compromised

Drug interactions must be excluded. Review all concurrent medications for CYP3A4 inhibitors or P-glycoprotein inhibitors that could increase rivaroxaban levels 3, 5.

Management Algorithm

If the biopsy confirms drug-induced pathology:

1. Calculate creatinine clearance - if <30 mL/min, rivaroxaban is contraindicated and likely accumulating 4, 3

2. Consider switching anticoagulation:

   • For cancer-associated thrombosis: LMWH is preferred over DOACs 2
   • For non-cancer PE: Consider warfarin or a different DOAC with less cutaneous reaction potential
   • Ensure minimum 3 months total anticoagulation for PE 2

3. Do not simply stop anticoagulation - this 78-year-old with recent PE remains at high risk for recurrent VTE 2, 6

4. Timing of switch: Can transition directly from rivaroxaban to LMWH or warfarin without bridging

The Methotrexate Consideration

While methotrexate can cause various cutaneous reactions including ulceration, papular eruptions, and even epidermal necrosis 7, 8, 9, 10, three weeks off the drug should show improvement if methotrexate were the sole cause. Methotrexate-induced skin toxicity typically improves within days to weeks of discontinuation, especially with supportive care.

However, consider methotrexate-induced immunosuppression may have unmasked an underlying process or increased susceptibility to other drug reactions 11.

Bottom Line

Strongly suspect rivaroxaban as the cause and proceed with anticoagulant substitution if the skin biopsy supports a drug reaction and other causes are excluded. The combination of advanced age, potential renal impairment, and persistent rash despite methotrexate cessation makes rivaroxaban the most likely ongoing culprit. Maintain anticoagulation throughout this transition given her recent PE.